dihexa human clinical trials or studies What is Dihexa? Benefits, mechanism, and uses for cognitive function DIHEXA – Research Peptide |

While historically listed with an "unknown status," recent data releases in late 2025 and early 2026 have clarified the safety profile that helped justify the Category 1 reclassification. Study Design: A randomized, placebo-controlled, double-blind Phase 1 pilot study

The tyrosine addition to AOD-9604 does a few things: Better stability The tyrosine at the N-terminus makes the molecule more resistant to enzymatic degradation, extending its functional half-life

Dosing & Reconstitution Guide Educational guide for reconstitution and common dosing patterns Standard / Conservative Approach (3 mL = 33.33 mg/mL

Adv Pediatr Infect Dis

Gall bladder/bile duct disease Acute pancreatitis and other pancreatic disorders have been reported, though the relationship to treatment is unclear Injection-site reactions Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Primary mechanism(s) of action Selectively binds and activates both GIP and GLP-1 receptors Example Tirzepatide (Mounjaro) Dosage Initial: 2.5 mg subcutaneous injection once weekly, titrated up to 5 mg weekly after 4 weeks If additional glycemic control is needed, dosage can be increased in 2.5 mg increments after at least 4 weeks on the current dosage